# PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve

Study · id `cardio:ct-nct03225001` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03225001](<https://clinicaltrials.gov/study/NCT03225001>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03225001

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 197 participants.

## Technical summary

Registry record NCT03225001. Allocation not applicable; no masking; primary purpose treatment. Start 2012-06-11 (actual); primary completion 2016-12-16 (actual). Results posted on 2018-01-09.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 197 participants (enrolled count; ClinicalTrials.gov record NCT03225001, source copy `cardio:ctgov-nct03225001-2021-03-09`, retrieved 2026-10-26)
- Started: 2012-06-11 (actual) (ClinicalTrials.gov record NCT03225001, source copy `cardio:ctgov-nct03225001-2021-03-09`, retrieved 2026-10-26)
- Primary completion: 2016-12-16 (actual) (ClinicalTrials.gov record NCT03225001, source copy `cardio:ctgov-nct03225001-2021-03-09`, retrieved 2026-10-26)
- Completion: 2020-10-28 (actual) (ClinicalTrials.gov record NCT03225001, source copy `cardio:ctgov-nct03225001-2021-03-09`, retrieved 2026-10-26)
- Results first posted: 2018-01-09 (ClinicalTrials.gov record NCT03225001, source copy `cardio:ctgov-nct03225001-2021-03-09`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT03225001, source copy `cardio:ctgov-nct03225001-2021-03-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03225001-2021-03-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve
- Acronym: PII NR3/ViV
- Condition: Aortic Stenosis
- Condition: Cardiomyopathy, Hypertrophic
- Intervention (Device): Edwards SAPIEN XT transcatheter valve, Model 9300TFX
- Lead sponsor: Edwards Lifesciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Edwards Lifesciences (`cardio:edwards-lifesciences`)

## Provenance

Content hash: cf08f9fb90ac07af45ed214c595648f6cdd60076fd6eb66655292bb0d7c48675
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
